Gene: ATXN1
Protein Name: Ataxin-1
Alternative Names: ATXN1, SCA1 protein
Molecular Weight: ~87 kDa (native), 95 kDa (predicted)
Amino Acids: 815
Location: Nucleus, Cytoplasm
Isoforms: Multiple isoforms due to alternative splicing
Ataxin-1 (encoded by the ATXN1 gene) is an 815-amino acid protein of the ATXN family, best known for its pathogenic role in Spinocerebellar Ataxia Type 1 (SCA1). In SCA1, a polymorphic CAG repeat expansion in the first exon of ATXN1 encodes an expanded polyglutamine (polyQ) tract, leading to toxic gain-of-function and neurodegeneration primarily in the cerebellum and brainstem [1][2].
Beyond SCA1, ATXN1 has been implicated in other neurodegenerative diseases and may play roles in Alzheimer's disease and Parkinson's disease through its functions in transcriptional regulation and RNA processing.
Ataxin-1 contains several functional domains:
| Domain | Position | Function |
|---|---|---|
| AXH domain | 471-603 | RNA/protein-binding, transcription regulation |
| PolyQ tract | ~250-350 | Pathogenic expansion in SCA1 (41-82 repeats normal, >41 pathogenic) |
| S/T-rich region | 320-400 | Phosphorylation sites, regulatory |
| Nuclear localization signal (NLS) | 768-785 | Nuclear import |
| Phosphorylation sites | Multiple | Regulation of toxicity |
The AXH (Atexin-1 Homology) domain is the signature functional element of ataxin-1:
The AXH domain is critical for both normal function and pathogenic interactions of ataxin-1.
The polyQ tract is located near the N-terminus:
The polyQ tract length correlates with:
In the normal brain, ataxin-1 participates in critical neuronal functions:
Ataxin-1 modulates gene expression through multiple mechanisms:
Transcription factor interaction: Ataxin-1 interacts with and modulates the activity of:
Chromatin remodeling: Ataxin-1 recruits histone modifiers and chromatin-remodeling complexes to target genes.
Co-activator/co-repressor: Functions as both co-activator and co-repressor depending on context and partner proteins.
Ataxin-1 directly regulates alternative splicing in neurons [1:1]:
Ataxin-1 localization is tightly regulated:
The expanded polyQ tract (>41 repeats) leads to disease through multiple mechanisms:
Protein misfolding: Expanded polyQ promotes misfolding and aggregation:
Nuclear inclusion formation: Characteristic pathological hallmark:
Transcriptional dysregulation: Altered gene expression patterns:
Selective neuronal vulnerability: Purkinje cells are particularly susceptible:
| Partner | Normal Function | Disease Relevance |
|---|---|---|
| RORα | Transcription factor | Cerebellar degeneration, disrupted in SCA1 |
| Capicua (CIC) | Transcriptional repressor | Expanded toxicity when mutated |
| GAp43 | Axonal growth | Contributes to neuronal dysfunction |
| PP2A (PPP2R2A) | Phosphatase | Modulates ataxin-1 toxicity |
| Ranbp2 | Nuclear pore protein | Modified in SCA1 [6] |
| Hsp70 | Molecular chaperone | Sequestered in inclusions |
| Ubc9 | SUMO conjugation | Altered SUMOylation in SCA1 |
Nuclear localization is essential for SCA1 pathogenesis [5:1]:
Emerging evidence suggests ataxin-1 involvement in AD:
ASO therapy targeting ATXN1 mRNA shows promise [7]:
Aggregation inhibitors: Prevent mutant ataxin-1 aggregation:
Transcription modulators: Correct dysregulated gene expression:
Neuroprotective agents: Support neuronal survival:
| Model | Type | Features |
|---|---|---|
| B05 | Transgenic mouse | Human ATXN1 with 82Q, Purkinje cell degeneration |
| SCA1-Q88 | Knock-in mouse | Expanded polyQ, progressive ataxia |
| Drosophila | Fruit fly model | Pan-neuronal ATXN1 expression |
| C. elegans | Worm model | PolyQ aggregation studies |
Factors influencing disease expression:
Zhang SS et al. Ataxin-1 regulates RNA splicing in neuronal cells. Nat Neurosci. 2015. ↩︎ ↩︎
Orr HT et al. Expansion of the polyglutamine repeat in ataxin-1. Nat Rev Neurosci. 2000. ↩︎
Bettencourt C et al. ATXN1 polyQ length and age of onset. Brain. 2013. ↩︎
Piel S et al. Mutant ataxin-1 in SCA1 pathogenesis. Nat Rev Neurol. 2013. ↩︎
Klement IA et al. Ataxin-1 nuclear localization is essential for SCA1. Cell. 1998. ↩︎ ↩︎
Tong X et al. Ranbp2 modulates GPU1 activity in SCA1. Nat Neurosci. 2011. ↩︎
Zu T et al. Antisense oligonucleotides for SCA1. Nat Med. 2019. ↩︎